Table 2 Biomarker serum levels with clinicopathological findings in ovarian cancer patients
| Â | Â | FRA (pg/mL) | MSLN (pg/mL) | MPF(pg/mL) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | N (%) | Mean | Median | SD | Range | Mean | Median | SD | Range | Mean | Median | SD | Range |
Normal | 60 (19%) | 341 | 324 | 122 | 176-696 | 11225 | 10300 | 4280 | 5169-26891 | 1869 | 1681 | 618 | 910-3691 |
Ovarian Cancer | 258†(81%) | 1680 | 549 | 5870 | 155-42523 | 43002 | 17279 | 61019 | 4274-311565 | 3602 | 2138 | 5994 | 717-72192 |
Histotype‡ |  |  |  |  |  |  |  |  |  |  |  |  |  |
Serous | 215 (83%) | 1616 | 586 | 3622 | 155-42523 | 48731 | 1681 | 62280 | 6322-311565 | 4275 | 2779 | 6446 | 717-72192 |
Endometrioid | 22 (9%) | 1862 | 434 | 5333 | 185-24843 | 38595 | 2138 | 64278 | 4274-240088 | 2786 | 1976 | 2887 | 1025-13492 |
Mucinous | 15 (6%) | 1047 | 497 | 2084 | 173-8475 | 20017 | 14632 | 19736 | 7672-88153 | 1875 | 1636 | 789 | 1071-4354 |
Stage | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
I | 78 (30%) | 1066 | 412 | 2876 | 162-24843 | 22654 | 14803 | 44258 | 4274-240088 | 2088 | 1686 | 1826 | 717-9075 |
II | 47 (18%) | 977 | 402 | 2877 | 164-8475 | 30439 | 15891 | 64662 | 6322-225597 | 2509 | 1807 | 3853 | 832-13492 |
III | 45 (17%) | 2014 | 775 | 5103 | 155-42523 | 58945 | 36112 | 69385 | 6370-257344 | 5887 | 3164 | 8499 | 858-72192 |
IV | 45 (17%) | 2811 | 1424 | 2477 | 241-14222 | 81160 | 19674 | 54307 | 8162-311565 | 4689 | 2196 | 5051 | 876-12882 |
Grade | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Low | 28 (11%) | 541 | 449 | 409 | 185-2178 | 25615 | 14947 | 46648 | 4274-257344 | 2263 | 1904 | 1904 | 717-10850 |
High | 148 (57%) | 2090 | 653 | 4579 | 162-42523 | 55768 | 20225 | 67979 | 6322-311565 | 4589 | 2299 | 7255 | 741-72192 |